Russian MedicineRussian Medicine0869-21062412-9100Eco-Vector3841510.18821/0869-2106-2017-23-2-107-112Review ArticleTHE PSYCHO-PHARMACOTHERAPY OF ANXIETY DISORDERS: PROBLEM ACTUAL VIEWShcherbakovaI. V-KrylatykhV. Yu-BardenshteynLeonid M.doctor of medical sciences, professor, head of the chair of psychiatry and narcology the A.E. Evdokimov Moscow state medical stomatological university, 127473, Moscow, Russian Federationbarden@mail.ruThe A.E. Evdokimov Moscow state medical stomatological universityThe center of mental health «Alyans»1504201723210711221072020Copyright © 2017, Eco-Vector2017The article presents review of modern publications related to pharmacological modes of treatment of anxiety disorders. Te analysis is applied to anxiolitic potential of psychotropic medications implemented in clinical practice considering their receptor profile, therapeutic characteristics and side effects. The national and foreign materials are summarized concerning application of anxiolitics, anti-convusants, antagonists of noradrenalin receptors, atypical anti-psychotics, anti-depressants in the capacity of monotherapy of isolated anxiety disorders. The data is presented concerning advantages and shortcomings of particular pharmacological groups, their differentiated efficacy under various nosologic forms of anxiety disorders. More minutely and comparatively the results and perspectives of exploration of therapeutic effect of modern antidepressants of double effect are examined much more minutely and comparatively. The conclusion about place and role of considered pharmacological classes of medications in treatment of anxiety disorders are presented.reviewanxiety disorderstherapyefficacytranquilizerantidepressantобзортревожные расстройстватерапияэффективностьтранквилизаторыантидепрессанты[Аведисова А.С. Контролирование симптомов тревоги и лечение тревожно-фобических расстройств - альтернатива или нет? Психиатрия и психофармакотерапия. 2006; 8 (5): 23-8.][Аведисова А.С., Ястребов Д.В., Алкеева-Костычева Е.К. Расстройства, возникающие при отмене бензодиазепиновых транквилизаторов. Психиатрия и психофармакотерапия. 2006; 8 (5): 20-3.][Александровский Ю.А., Барденштейн Л.М., Аведисова А.С. Психофармакотерапия пограничных психических расстройств. М.: ГЭОТАР-Медицина; 2000.][Барденштейн Л.М. Венлафаксин (велаксин) - современный антидепрессант двойного действия. Психиатрия. 2005; (6): 62-5.][Бобров А.Е. Тревожные расстройства: их систематика, диагностика и фармакотерапия. Российский медицинский журнал. 2006; 14 (4): 328-32.][Болдуин Д. Антидепрессанты в лечении тревожных расстройств. В кн.: Краснов В.Н., ред. Терапия антидепрессантами и другие методы лечения депрессивных расстройств. Доклад рабочей группы CINP на основе обзора доказательных данных. М.; 2008: 123-35.][Вельтищев Д.Ю., Марченко А.С. Генерализованное тревожное расстройство: проблемы диагностики, прогноза, психофармакотерапии. Современная терапия психических расстройств. 2013; (1): 17-23.][Левин О.С. Применение буспирона в клинической практике. Журнал неврологии и психиатрии им. С.С. Корсакова. 2015; 115 (4): 83-7.][Монтгомери С.А. Прегабалин при лечении генерализированного тревожного расстройства (расширенный реферат). Психические расстройства в общей медицине. 2010; (1): 3-6.][Мосолов С.Н., Алфимов П.В. Алгоритм биологической терапии генерализованного тревожного расстройства. Современная терапия психических расстройств. 2015; (2): 24-8.][Осадший Ю.Ю., Вобленко Р.А., Арчаков Д.С., Тараканова Е.А. Место бензодиазепинов в современной терапии психических расстройств (обзор доказательных исследований). Современная терапия психических расстройств. 2016; (1): 2-16.][Чахава В.О., Лесс Э.Ю., Борукаев Р.Р. Эффективность применения венлафаксина при генерализованном тревожном расстройстве. Российский психиатрический журнал. 2007; (2): 85-9.][Ястребов Д.В. Смена антидепрессивной терапии; причины и тактика. Лечебное дело. 2007; (3): 53-9.][Albert U., Aguglia E., Maina G., Bogetto F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry. 2002; 63 (11): 1004.][Ammar G., Naja W.J., Pelissolo A. Treatment-resistant anxiety disorders: A literature review of drug therapy strategies. Encephale. 2015; 41 (3): 260-5. (in French)][Anderberg J., Bogren M., Mattisson C., Brådvik L. Long-Term Suicide Risk in Anxiety-The Lundby Study 1947-2011. Arch. Suicide Res. 2016; 20 (3): 463-75.][Andrisano C., Chiesa A., Serretti A. Newer antidepressants and panic disorder: a meta-analysis. Int. Clin. Psychopharmacol. 2013; 28 (1): 33-45.][Baldwin D., Woods R., Taylor D. Efficacy of drug treatments for generalised anxiety disorder: systematic review and meta-analysis. BMJ. 2011; 342: d1199.][Baldwin D.S., Schweizer E., Xu Y., Lyndon G. Does early improvement predict endpoint response in patients with generalized anxiety disorder (GAD) treated with pregabalin or venlafaxine XR? Eur. Neuropsychopharmacol. 2012; 22 (2): 137-42.][Bandelow B., Boerner J.R., Kasper S., Linden M., Wittchen H.U., Möller H.J. The diagnosis and treatment of generalized anxiety disorder. Dtsch. Arztebl. Int. 2013; 110 (17): 300-9.][Bandelow B., Reitt M., Röver C., Michaelis S., Görlich Y., Wedekind D. Efficacy of treatments for anxiety disorders: a meta-analysis. Int. Clin. Psychopharmacol. 2015; 30 (4): 183-92.][Bandelow B., Zohar J., Hollander E., Kasper S., Möller H.J., WFSBP Task Forse on Treatment Guidelines for Anxiety, Obsessive-compulsive, Post-traumatic Stress Disorders et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders - first revision. World J. Biol. Psychiatry. 2008; 9 (4): 248-312.][Blanco C, Heimberg R.G., Schneier F.R., Fresco D.M., Chen H., Turk C.L. et al. A placebo-controlled trial of phenelzine, cognitive behavioral group therapy, and their combination for social anxiety disorder. Arch. Gen. Psychiatry. 2010; 67 (3): 286-95.][Blaya C., Seganfredo A.C., Dornelles M., Torres M., Paludo A., Heldt E. et al. The efficacy of milnacipran in panic disorder: an open trial. Int. Clin. Psychopharmacol. 2007; 22 (3): 153-8.][Griffin C.E. 3rd1, Kaye A.M., Bueno F.R., Kaye A.D. Benzodiazepine Pharmacology and Central Nervous System-Mediated Effects. Ochsner J. 2013; 13 (2): 214-23.][Chouinard G. The search for new antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. J. Psychiatry Neurosci. 2006; 31 (3): 168-76.][Conway K.P., Compton W., Stinson F.S., Grant B.F. Lifetime comorbidity of DSM-IV mood and anxiety disorders and specific drug use disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. J. Clin. Psychiatry. 2006; 7 (2): 247-57.][Coplan J.D., Aaronson C.J., Panthangi V., Kim Y. Treating comorbid anxiety and depression: Psychosocial and pharmacological approaches. World J. Psychiatry. 2015; 5 (4): 366-78.][Davis M.L., Smits J.A., Hofmann S.G. Update on the efficacy of pharmacotherapy for social anxiety disorder: a meta-analysis. Expert Opin. Pharmacother. 2014; 15 (16): 2281-91.][Dell'Osso B., Palazzo M.C., Oldani L., Altamura A.C. The noradrenergic action in antidepressant treatments: pharmacological and clinical aspects. CNS Neurosci. Ther. 2011; 17 (6): 723-32.][Depping A.M., Komossa K., Kissling W., Leucht S. Second-generation antipsychotics for anxiety disorders. Cochrane Database Syst. Rev. 2010; (12): CD008120.][Dougherty D.D., Corse A.K., Chou T., Duffy A., Arulpragasam A.R., Deckersbach T. et al. Open-label study of duloxetine for the treatment of obsessive-compulsive disorder. Int. J. Neuropsychopharmacol. 2015; 18 (2).][Flockhart D.A. Dietary restrictions and drug interactions with monoamine oxidase inhibitors: an update. J. Clin. Psychiatry. 2012; 73 (Suppl. 1): 17-24.][Freire R.C., Machado S., Arias-Carrion O., Nardi A.E. Current pharmacological interventions in panic disorder. CNS Neurol. Disord. Drug Targets. 2014; 13 (6): 1057-65.][Gelenberg A.J., Lydiard R.B., Rudolph R.L., Aguiar L., Haskins J.T., Salinas E. Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: A 6-month randomized controlled trial. JAMA. 2000; 283 (23): 3082-8.][Gordon M., Melvin G. Selective serotonin re-uptake inhibitors - a review of the side effects in adolescents. Aust. Fam. Physician. 2013; 42 (9): 620-3.][Guaiana G., Barbui C., Cipriani A. Hydroxyzine for generalised anxiety disorder. Cochrane Database Syst. Rev. 2010; 8 (12): CD006815.][Huh J., Goebert D., Takeshita J., Lu B.Y., Kang M. Treatment of Generalized Anxiety Disorder: A Comprehensive Review of the Literature for Psychopharmacologic Alternatives to Newer Antidepressants and Benzodiazepines. Prim. Care Companion CNS Disord. 2011; 13 (2).][Katz I.R., Reynolds C.F., Alexopoulos G.S., Hackett D. Venlafaxine ER as a treatment for generalized anxiety disorder in older adults: pooled analysis of five randomized placebo-controlled clinical trials. J. Am. Geriatr. Soc. 2002; 50 (1): 18-25.][Kjernisted K., McIntosh D. Venlafaxine extended release (XR) in the treatment of panic disorder. Ther. Clin. Risk Manag. 2007; 3 (1): 59-69.][Kornstein S.G., Russell J.M., Spann M.E., Crits-Christoph P., Ball S.G. Duloxetine in the treatment of generalized anxiety disorder. Expert Rev. Neurother. 2009; 9 (2): 155-65.][LaLonde C.D., Van Lieshout R.J., Treating generalized anxiety disorder with second generation antipsychotics: a systematic review and meta-analysis. J. Clin. Psychopharmacol. 2011; 31 (3): 326-33.][Levitan M.N., Papelbaum M., Nardi A.E. Profile of agomelatine and its potential in the treatment of generalized anxiety disorder. Neuropsychiatr. Dis. Treat. 2015; 11: 1149-55.][Liebowitz M.R., Mangano R.M., Bradwejn J., Asnis G, SAD Study Group. A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J. Clin. Psychiatry. 2005; 66 (2): 238-47.][Marazziti D., Carlini M., Dell'Osso L. Treatment strategies of obsessive-compulsive disorder and panic disorder/agoraphobia. Curr. Top. Med. Chem. 2012; 12 (4): 238-53.][Marchand A, Coutu M.F., Dupuis G., Fleet R., Borgeat F., Todorov C. et al. Treatment of panic disorder with agoraphobia: randomized placebo-controlled trial of four psychosocial treatments combined with imipramine or placebo. Cogn. Behav. Ther. 2008; 37 (3): 146-59.][Montgomery S.A. Tolerability of serotonin norepinephrine reuptake inhibitor antidepressants. CNS Spectr. 2008; 13 (Suppl. 11): 27-33.][Naoi M., Riederer P., Maruyama W. Modulation of monoamine oxidase (MAO) expression in neuropsychiatric disorders: genetic and environmental factors involved in type A MAO expression. J. Neural. Transm. (Vienna). 2016; 123 (2): 91-106.][Pollack M., Mangano E., Simon N.M., Zhang Y. A randomized controlled trial of venlafaxine ER and paroxetine in the treatment of outpatients with panic disorder. Psychopharmacology. 2007; 194 (2): 233-42.][Pollack M.H., Tiller J., Xie F., Trivedi M.H. Tiagabine in adult patients with generalized anxiety disorder: results from 3 randomized, double-blind, placebo-controlled, parallel-group studies. J. Clin. Psychopharmacol. 2008; 28 (3): 308-16.][Ravindran L.N., Stein M.B. The pharmacologic treatment of anxiety disorders: a review of progress. J. Clin. Psychiatry. 2010; 71 (7): 839-54.][Scott A., Davidson A., Palmer K. Antidepressant drugs in the treatment of anxiety disorders. Adv. Psychiatr. Treat. 2001; 7 (4): 275-82.][Steenen S.A., van Wijk A.J., van der Heijden Geert JMG, van Westrhenen R., de Lange J., de Jongh A. Propranolol for the treatment of anxiety disorders: Systematic review and meta-analysis. J. Psychopharmacol. 2016; 30 (2): 128-39.][Taylor D., Lenox-Smith A., Bradley A. A review of the suitability of duloxetine and venlafaxine for use in patients with depression in primary care with a focus on cardiovascular safety, suicide and mortality due to antidepressant overdose. Ther. Adv. Psychopharmacol. 2013; 3 (3): 151-61.][Van Ameringen M., Mancini C., Patterson B., Simpson W. Pharmacotherapy for social anxiety disorder: an update. Isr. J. Psychiatry Relat. Sci. 2009; 46 (1): 53-61.][Wittchen H.U., Jacobi F., Rehm J., Gustavsson A., Svensson M., Jönsson B. et al. The size and burden of mental disorders and other disorders of the brain in Europe 2010. Eur. Neuropsychopharmacol. 2011; 21 (9): 655-79.]